Cargando…
Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients
BACKGROUND: Recent studies have reported TIMs play an important role in tumors progression or regression, but the effect of TIMs in biliary tract cancer remains unclear. The aim of this study is to investigate the prognostic value of tumor infiltrating mast cells (TIMs) and its influence on gemcitab...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863450/ https://www.ncbi.nlm.nih.gov/pubmed/29562907 http://dx.doi.org/10.1186/s12885-018-4220-1 |
_version_ | 1783308392442363904 |
---|---|
author | Bo, Xiaobo Wang, Jie Suo, Tao Ni, Xiaoling Liu, Han Shen, Sheng Li, Min Wang, Yueqi Liu, Houbao Xu, Jiejie |
author_facet | Bo, Xiaobo Wang, Jie Suo, Tao Ni, Xiaoling Liu, Han Shen, Sheng Li, Min Wang, Yueqi Liu, Houbao Xu, Jiejie |
author_sort | Bo, Xiaobo |
collection | PubMed |
description | BACKGROUND: Recent studies have reported TIMs play an important role in tumors progression or regression, but the effect of TIMs in biliary tract cancer remains unclear. The aim of this study is to investigate the prognostic value of tumor infiltrating mast cells (TIMs) and its influence on gemcitabine-based adjuvant chemotherapy (ACT) benefits in biliary tract cancer patients after surgery. METHODS: TIMs were evaluated by immunohistochemical staining of tryptase in 250 patients with resected gallbladder carcinoma (GBC) or extrahepatic bile duct carcinoma (EBDC) from Zhongshan Hospital. The relationships between TIMs and clinicopathological factors and postoperative prognosis were analyzed respectively. RESULTS: High TIMs infiltration was significantly correlated with prolonged overall survival (OS). Furthermore, multivariate analysis indicated TNM stage and TIMs as independent prognostic factors for OS. Patients with high TIMs infiltration appeared to significantly benefit from Gemcitabine-based ACT in the discovery and validation cohorts. Spearman analysis identified that TIMs infiltration were positively correlated with anti-tumor CD8+ T cells. CONCLUSION: TIMs infiltration is an independent favorable prognostic factor in GBC and EBDC patients, which could better stratify patients with different prognosis and predict benefit from gemcitabine-based ACT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4220-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5863450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58634502018-03-27 Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients Bo, Xiaobo Wang, Jie Suo, Tao Ni, Xiaoling Liu, Han Shen, Sheng Li, Min Wang, Yueqi Liu, Houbao Xu, Jiejie BMC Cancer Research Article BACKGROUND: Recent studies have reported TIMs play an important role in tumors progression or regression, but the effect of TIMs in biliary tract cancer remains unclear. The aim of this study is to investigate the prognostic value of tumor infiltrating mast cells (TIMs) and its influence on gemcitabine-based adjuvant chemotherapy (ACT) benefits in biliary tract cancer patients after surgery. METHODS: TIMs were evaluated by immunohistochemical staining of tryptase in 250 patients with resected gallbladder carcinoma (GBC) or extrahepatic bile duct carcinoma (EBDC) from Zhongshan Hospital. The relationships between TIMs and clinicopathological factors and postoperative prognosis were analyzed respectively. RESULTS: High TIMs infiltration was significantly correlated with prolonged overall survival (OS). Furthermore, multivariate analysis indicated TNM stage and TIMs as independent prognostic factors for OS. Patients with high TIMs infiltration appeared to significantly benefit from Gemcitabine-based ACT in the discovery and validation cohorts. Spearman analysis identified that TIMs infiltration were positively correlated with anti-tumor CD8+ T cells. CONCLUSION: TIMs infiltration is an independent favorable prognostic factor in GBC and EBDC patients, which could better stratify patients with different prognosis and predict benefit from gemcitabine-based ACT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-4220-1) contains supplementary material, which is available to authorized users. BioMed Central 2018-03-21 /pmc/articles/PMC5863450/ /pubmed/29562907 http://dx.doi.org/10.1186/s12885-018-4220-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Bo, Xiaobo Wang, Jie Suo, Tao Ni, Xiaoling Liu, Han Shen, Sheng Li, Min Wang, Yueqi Liu, Houbao Xu, Jiejie Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients |
title | Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients |
title_full | Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients |
title_fullStr | Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients |
title_full_unstemmed | Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients |
title_short | Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients |
title_sort | tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863450/ https://www.ncbi.nlm.nih.gov/pubmed/29562907 http://dx.doi.org/10.1186/s12885-018-4220-1 |
work_keys_str_mv | AT boxiaobo tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients AT wangjie tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients AT suotao tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients AT nixiaoling tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients AT liuhan tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients AT shensheng tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients AT limin tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients AT wangyueqi tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients AT liuhoubao tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients AT xujiejie tumorinfiltratingmastcellspredictprognosisandgemcitabinebasedadjuvantchemotherapeuticbenefitinbiliarytractcancerpatients |